Dr. Darlene
McCord, a well-respected biochemist from Iowa, USA is here in Manila to share her skin and wound care products with the Philippine market.
Dr. McCord
is the Senior Researcher of McCord Research, a research company focused on
finding scientifically proven solutions to common health problems. She
specializes in corneotherapy for treatment of skin disorders and wounded skin.
Ten years of
painstaking research led her to discover the cell-regenerating properties of
the olive. Later, she would develop a line of skin and wound care products
containing her patent pending, breakthrough ingredient Olivamine10ä. Olivamine10ä, under the parent company Pinnaclife, has been proven
to treat wounds faster and more effectively than any other commercially
available wound treatment. These became the best-selling products in hospitals,
nursing homes and other medical institutions in the US following the launch in
2004.
Now,
Filipinos can finally have access to Pinnaclife products.
Cambert
Pilipinas Inc. will be launching Dr. McCord’s Olivamine10ä-based
products here in Manila through medical practitioners. Like Pinnaclife, Cambert
puts a premium on finding natural solutions to common health woes—a healthier
alternative to harsh chemicals found in traditional treatments.
Cambert will
introduce the Pinnaclife Wound Care System developed by Dr. McCord, which
includes an antiseptic cleanser, and topical skin solutions,—each specifically
designed to help treat wounds and skin irritations of different kinds and
severity.
These
products are made to complement each other by forming a “system” that enables
rapid wound healing by nourishing cells in the body, instead of causing further
damage to delicate skin as some traditional cures do.
In her
decades of experience, Dr. McCord has been awarded two US patents and six
medical devices, along with over 30 skin care products available all over the
world. Dr. McCord’s work has also been published in peer-reviewed journals and
other publications.
Dr. McCord
is the author of “Living Well at One Hundred.”
No comments:
Post a Comment